ROIV

Roivant SciencesC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-11

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$32.98

+13.5% vs current

Most likely

Base case

60%

Probability

Target price

$25.37

-12.7% vs current

B-

Bear case

20%

Probability

Target price

$20.30

-30.1% vs current

AI sentiment snapshot

Latest data as of 2026-02-07

AI commentary

Market consensus shows a mixed-to-neutral positioning with median analyst targets near current levels; coverage includes a range from low (~$20) to high (~$34) that implies divergent views [#SERP-3], [#SERP-5]. Short-term sentiment may hinge on upcoming corporate updates and coverage refreshes, while longer-term tone will track clinical readouts and capital dynamics [#SERP-2].

RankAlpha Sentiment AI - 2026-02-07

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-03-31eventAnalyst coverage refreshHigh impact

Consensus and target updates from coverage changes that can shift headline targets and sentiment; date set to the assumed refresh window end [#SERP-4].

2026-05-08catalystQuarterly/corporate updateHigh impact

Quarterly results or a corporate update that could change guidance or cash outlook; conservatively dated when no formal SEC date exists [#SERP-3].

2027-02-07catalystMajor clinical/regulatory milestoneHigh impact

A pivotal clinical readout or regulatory decision for a lead asset that would materially re-rate valuation; timeline set conservatively when no single public date is available [#SERP-2][#SERP-5].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-02-07 • Updated nightlySource: Internal modelMethodology